Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report...

Related Keywords

Xencor Xmab ,Exchange Commission ,Xencor Inc ,Nasdaq ,Private Securities Litigation Reform Act ,Markets ,